Back Pain Is a Hallmark of Aging. A Growth Factor and SIRT1 Might Slow It Down
Spinal disc degeneration affects almost everyone as they age and is a leading cause of chronic back pain.
Intervertebral discs are the spine’s shock absorbers: cartilaginous cushions between vertebrae that enable movement and distribute mechanical load. With age, they lose water content, height, and elasticity — a process called intervertebral disc degeneration (IDD). The consequences are common and often debilitating: back pain, radiating pain into legs or arms, restricted mobility. IDD is one of the most studied targets in anti-aging biology precisely because it is so universal.
FGF21 as a molecular switch
FGF21 is a growth factor already known for its effects on metabolism and aging. In a new study published in Aging Cell, researchers investigated what happens when FGF21 production in intervertebral disc cells is boosted. The result: FGF21 upregulates SIRT1, a sirtuin protein involved in DNA repair, inflammation control, and cell survival. In a rat model of artificially induced disc degeneration, FGF21 intervention led to measurably less cellular senescence in disc tissue, reduced inflammation, and better preservation of structural disc integrity.
The mechanistic logic is straightforward. SIRT1 activity declines with age, and that decline accelerates senescence in disc cells. By activating the FGF21-SIRT1 axis, that aging cascade is temporarily braked. The approach fits a broader trend in longevity science: targeting the biological processes that cause disease rather than treating symptoms after the damage is done.
From rat spine to human clinic: a long road
The limitations are clear. This is an animal model with artificially induced degeneration in a species with very different spinal biomechanics than humans. Whether FGF21 administration is safe and effective in human disc degeneration is entirely unknown. FGF21 is also a systemically acting growth factor with effects across multiple organs — targeted delivery to the spine is a separate engineering challenge. That said, the mechanistic foundation is solid enough to justify further investigation. Chronic back pain is one of the leading causes of disability worldwide. Any biologically grounded approach that slows its progression deserves serious attention, even if clinical application remains a distant prospect.